Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

9.15USD
9 Dec 2016
Change (% chg)

$0.28 (+3.16%)
Prev Close
$8.87
Open
$8.96
Day's High
$9.19
Day's Low
$8.90
Volume
315,855
Avg. Vol
367,132
52-wk High
$9.20
52-wk Low
$3.64

Select another date:

Mon, Nov 7 2016

BRIEF-Progenics announces $50 million RELISTOR royalty-backed financing

* Progenics announces $50 million RELISTOR royalty-backed financing

BRIEF-Valeant and Progenics announce the U.S. commercial launch of FDA-approved Relistor tablets

* Valeant and Progenics announce the U.S. commercial launch of FDA approved Relistor tablets Source text for Eikon: Further company coverage:

Progenics Pharmaceuticals whistleblower wins another $3 million

A former Progenics Pharmaceuticals Inc chemist who last year won a $1.66 million verdict from a biotechnology company accused of retaliating against him for whistleblower claims was awarded at least $3.3 million more on Tuesday.

BRIEF-Progenics Pharmaceuticals Q2 loss per share $0.08

* Progenics Pharmaceuticals announces second quarter 2016 financial and business results

BRIEF-Valeant and Progenics announce FDA approvals for relistor

* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016

BRIEF-Progenics Pharmaceuticals signs commercial license agreement with Selexis SA

* Under agreement, progenics will have use of Selexis CHO-M cell line and sure technology platform

Select another date: